Cogent Biosciences, Inc. (COGT)
COGT moved a median of +0.06% 30 minutes after news, and +0.22% by the close. How COGT actually reacts to news — the realized, point-in-time move the market made, measured across 271 labeled events over the last three years with zero look-ahead.
COGT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.14% | 45% | 271 |
| 30-min | +0.06% | 51% | 271 |
| 60-min | -0.40% | 45% | 271 |
| to close | +0.22% | 53% | 266 |
| Middle 50% of COGT reactions | -1.42% to +1.19% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 271 |
Half of all Cogent Biosciences, Inc. news events land between -1.42% and +1.19% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How COGT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.79% | 70% | -1.75% |
| Analyst downgrades | 11 | +1.42% | 100% | +3.45% |
| Coverage initiations | 16 | +2.07% | 75% | +0.27% |
| Rating reiterations | 101 | +0.06% | 52% | +0.26% |
| Price-target raises | 20 | +0.11% | 55% | +0.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how COGT ranks against every other measured name →
That’s how COGT usually reacts — get an email when it moves on news →Email me when COGT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to COGT's baseline. Nothing else.
Recent COGT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | Press release | GlobeNewswire | -0.41% | -1.89% | |
| Form 8-K Cogent Biosciences, Inc. For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | +0.14% | |
| Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.67% | — | |
| Form 8-K Cogent Biosciences, Inc. For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | — | |
| Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Press release | GlobeNewswire | -0.85% | -0.10% | |
| Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | Press release | GlobeNewswire | -0.35% | +1.66% | |
| Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | Press release | GlobeNewswire | -0.35% | +1.66% | |
| Form 8-K Cogent Biosciences, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | +1.66% | |
| Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Press release | GlobeNewswire | +0.64% | -0.17% | |
| Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST | Press release | GlobeNewswire | +1.61% | +2.67% | |
| Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.07% | +1.74% | |
| Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | Press release | GlobeNewswire | -0.44% | +1.71% | |
| Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.05% | +0.16% | |
| Form 10-Q Cogent Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.05% | +0.16% | |
| Form 8-K Cogent Biosciences, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | +0.16% | |
| Form ARS Cogent Biosciences, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.54% | +1.15% | |
| Form DEF 14A Cogent Biosciences, Inc. For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -0.54% | +1.15% | |
| Form DEFA14A Cogent Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.54% | +1.15% | |
| Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Press release | GlobeNewswire | -0.46% | -0.86% | |
| Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | Press release | GlobeNewswire | +0.07% | +0.73% | |
| Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Press release | GlobeNewswire | -5.20% | -6.72% | |
| Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) | Press release | GlobeNewswire | +0.83% | -3.02% | |
| Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Press release | GlobeNewswire | +0.72% | +3.62% | |
| Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.61% | +4.38% | |
| Form 10-K Cogent Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.61% | +4.38% | |
| Form 8-K Cogent Biosciences, Inc. For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | +4.38% | |
| Form S-8 Cogent Biosciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | +4.35% | +0.92% | |
| Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting | Press release | GlobeNewswire | -0.40% | -0.45% | |
| Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | Press release | GlobeNewswire | +3.04% | +4.64% | |
| Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) | Press release | GlobeNewswire | +2.19% | +5.39% | |
| Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | Press release | GlobeNewswire | -0.46% | +0.72% | |
| Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.35% | +0.93% | |
| Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | Press release | GlobeNewswire | -0.54% | -2.11% | |
| Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | Press release | GlobeNewswire | -0.46% | -6.43% | |
| Form 8-K Cogent Biosciences, Inc. For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | -3.65% | |
| Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) | Press release | GlobeNewswire | -0.46% | -6.43% | |
| Form 8-K Cogent Biosciences, Inc. For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +2.29% | +4.77% | |
| Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +4.30% | +4.62% | |
| Form 8-K Cogent Biosciences, Inc. For: Nov 11 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | — | |
| Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 | Press release | GlobeNewswire | -0.01% | +7.66% | |
| Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock | Press release | GlobeNewswire | -3.18% | +7.42% | |
| Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST) | Press release | GlobeNewswire | -2.48% | -0.82% | |
| Form 8-K Cogent Biosciences, Inc. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -2.48% | -0.82% | |
| Form 10-Q Cogent Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.48% | -0.82% | |
| Form S-3ASR Cogent Biosciences, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -2.48% | -0.82% | |
| Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting | Press release | GlobeNewswire | +1.42% | -4.62% | |
| Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.42% | -4.62% | |
| Form 8-K Cogent Biosciences, Inc. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | +1.42% | -4.62% | |
| Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Press release | GlobeNewswire | +0.34% | +1.61% | |
| Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Press release | GlobeNewswire | -0.80% | -3.45% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the COGT section they belong to.
Where else COGT is measured.
COGT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cogent Biosciences, Inc.'s median reaction calculated?
Every labeled COGT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 271 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of COGT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does COGT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.